Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Maurice Wilkins Centre for Molecular Biodiscovery, University of Otago, Dunedin, New Zealand.
Mamm Genome. 2018 Dec;29(11-12):831-842. doi: 10.1007/s00335-018-9758-3. Epub 2018 Jul 10.
This review paper outlines studies on the Δ122p53 mouse, a model of the human Δ133p53 isoform, together with studies in other model organisms, cell culture, and where available, clinical investigations. In general, these studies imply that, in contrast to the canonical p53 tumor suppressor, Δ133p53 family members have oncogenic capability. Δ122p53 is multi-functional, conferring survival and proliferative advantages on cells, promoting invasion, metastasis and vascularization, as does Δ133p53. Cancers with high levels of Δ133p53 often have poor prognosis. Δ122p53 mediates its effects through the JAK-STAT and RhoA-ROCK signaling pathways. We propose that Δ133p53 isoforms have evolved as inflammatory signaling molecules to deal with the consequent tissue damage of p53 activation. However, if sustained expression of the isoforms occur, pathologies may result.
这篇综述论文概述了对Δ122p53 小鼠(一种人源Δ133p53 同种型的模型)的研究,以及其他模式生物、细胞培养的研究,以及在可用的情况下,临床研究。一般来说,这些研究表明,与典型的 p53 肿瘤抑制因子相反,Δ133p53 家族成员具有致癌能力。Δ122p53 具有多功能性,赋予细胞生存和增殖优势,促进侵袭、转移和血管生成,Δ133p53 也是如此。高水平表达Δ133p53 的癌症通常预后不良。Δ122p53 通过 JAK-STAT 和 RhoA-ROCK 信号通路来发挥其作用。我们提出,Δ133p53 同种型已经进化为炎症信号分子,以应对 p53 激活导致的组织损伤。然而,如果同种型持续表达,可能会导致病理变化。